Synergistic effect of tanshinone IIA and mesenchymal stem cells on preventing learning and memory deficits via anti-apoptosis, attenuating tau phosphorylation and enhancing the activity of central cholinergic system in vascular dementia

Kong, Deyan; Liu, Qian; Xu, Guangxu; Huang, Zhenhua; Luo, Na; Huang, Yuanheng; Cai, Keshu

doi:10.1016/j.neulet.2016.11.024

Cited by 20 publications

(8 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, a potential clinical benefit is expected from the combination of hMSCs‐based therapy with other novel therapeutic agents. To date, several compounds have shown a synergistic effect upon combined treatment with hMSCs in models of stroke and dementia and combined transplantation of multiple cell‐type is clinically examined in patients with stroke .…”

Section: Efficacy and Limitations Of Hmscs‐based Therapymentioning

confidence: 99%

Concise Review: Mesenchymal Stem Cells in Neurodegenerative Diseases

2017

View full text Add to dashboard Cite

Stem cell-based therapies for neurodegenerative diseases aim at halting clinical deterioration by regeneration and by providing local support for damaged tissue. Mesenchymal stem cells (MSCs) hold great potential for cell therapy as they can be efficiently derived from adult tissue, ex vivo expanded in culture and safely transplanted autologously. MSCs were also shown to be able to differentiate toward neural fates and to secrete a broad range of factors able to promote nervous tissue maintenance and repair. Moreover, upon transplantation, MSCs were shown capable of homing toward lesioned areas, implying their potential use as vehicles for therapeutic agents administration. Indeed, various advantageous effects were reported following human MSCs transplantation into rodent models of neurodegenerative diseases, such as neurotrophic factormediated protection, enhanced neurogenesis, modulation of inflammation, and abnormal protein aggregate clearance. Recent studies have also used ex vivo manipulation for enhanced expression of potentially favorable factors, by so exploiting the homing capacity of MSCs for effective expression at the lesion site. Here, we will summarize current advancements in MSCs-based therapies for neurodegenerative diseases. We will examine the roles of central mechanisms suggested to mediate the beneficial effects of MSCs-based therapy and consider the augmentation of these mechanisms for superior clinical outcomes in rodent models of neurodegeneration as well as in clinical trials. STEM CELLS 2017;35:1867-1880 SIGNIFICANCE STATEMENTMesenchymal stem cells (MSCs) hold great potential as source for cell-based therapy for neurodegenerative diseases. In this review, we summarize recent progress using human MSC transplantation into rodent models of neurodegeneration. We examine the molecular mechanisms mediating disease amelioration through this approach and emphasize the potential of ex vivo manipulation for these cells before transplantation.

show abstract

Section: Efficacy and Limitations Of Hmscs‐based Therapymentioning

confidence: 99%

Concise Review: Mesenchymal Stem Cells in Neurodegenerative Diseases

2017

View full text Add to dashboard Cite

show abstract

“…In addition, Tan IIA effectively induced the differentiation of cord blood MSCs into liver cells in a rat model of cirrhosis (Yang et al, 2015), BMSCs into neuronal cells in a rat spinal cord injury model (Zhang et al, 2018), and placental MSCs into cardiomyocytes in vitro (Li K. et al, 2018). Furthermore, it has been reported that Tan IIA combined with MSC treatment exhibited a neuronal protective effect via suppression of neuronal apoptosis in a vascular dementia rat model (Kong et al, 2017), as well as by suppressing amyloid-related protein production and inflammation in an Aβ25-35-induced AD rat model (Huang et al, 2019).…”

Section: Tanshinone Iiamentioning

confidence: 99%

Recruitment of Mesenchymal Stem Cells to Damaged Sites by Plant-Derived Components

Maeda

2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are capable of differentiating into a limited number of diverse cells and secrete regenerative factors that contribute to the repair of damaged tissue. In response to signals emitted by tissue damage, MSCs migrate from the bone marrow and area surrounding blood vessels within tissues into the circulating blood, and accumulate at the site of damage. Hence, MSC transplantation therapy is beginning to be applied to the treatment of various intractable human diseases. Recent medicinal plants studies have shown that plant-derived components can activate cell functions. For example, several plant-derived components activate cell signaling pathways, such as phosphatidylinositol 3-kinase and mitogen-activated protein kinase (MAPK), enhance expression of the CXCL12/CXCR4 axis, stimulate extracellular matrix remodeling, and consequently, promote cell migration of MSCs. Moreover, plant-derived components have been shown to promote recruitment of MSCs to damaged tissues and enhance healing in disease models, potentially advancing their therapeutic use. This article provides a comprehensive review of several plant-derived components that activate MSC migration and homing to damaged sites to promote tissue repair.

show abstract

“…Tanshinone IIA was reported to inhibit the expression of Tau in nerve cells (Kong et al, 2016;Li, Han, & Wu, 2016;Shi et al, 2012). In addition, Tanshinone IIA also showed estrogenic activity and targeted estrogen receptor (Fan et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

Cytotoxicity of Tanshinone IIA combined with Taxol on drug‐resist breast cancer cells MCF‐7 through inhibition of Tau

Lin

Zheng

Xie

et al. 2018

Phytotherapy Research

View full text Add to dashboard Cite

Drug resistance represents a major obstacle to improving the overall response and survival of cancer patients. Taxol is one of the most commonly used chemotherapy agents in breast cancer. As with many cancer therapeutic agents, resistance remains a significant problem when using Taxol to treat malignancies. In this study, estrogen receptor positive breast cancer cells MCF-7 were induced Taxol resistance. And Tanshinone IIA combined with Taxol was chosen to treat it. The drugs combination showed additive effect in most drug concentrations. Drug resistance cancer cells showed a higher microtubule associated protein (Tau) expression, which was considered as one of the reasons for Taxol resistance. Tanshinone IIA inhibited the expression of Tau in MCF-7 cells and resulted in higher sensibility of Taxol. Moreover, Tanshinone IIA also showed cytotoxicity to MCF-7, which might be related to its estrogenicity effect. In conclusion, the combination of Tanshinone IIA and Taxol showed higher cytotoxicity to Taxol resistant MCF-7 cells, which might be related to the inhibition of Tau.

show abstract

Synergistic effect of tanshinone IIA and mesenchymal stem cells on preventing learning and memory deficits via anti-apoptosis, attenuating tau phosphorylation and enhancing the activity of central cholinergic system in vascular dementia

Cited by 20 publications

References 31 publications

Concise Review: Mesenchymal Stem Cells in Neurodegenerative Diseases

Concise Review: Mesenchymal Stem Cells in Neurodegenerative Diseases

Recruitment of Mesenchymal Stem Cells to Damaged Sites by Plant-Derived Components

Cytotoxicity of Tanshinone IIA combined with Taxol on drug‐resist breast cancer cells MCF‐7 through inhibition of Tau

Contact Info

Product

Resources

About